INTRODUCTION Methicillin-resistant Staphylococcus aureus (MRSA) is an established nosocomial pathogen that causes infections, such as bacteremia, respiratory tract infections, skin and soft tissue infections (SSTIs), bone and joint infections, and urinary tract infections (1, 2). The prevalence rate of hospital-acquired MRSA infections was the highest (>50) in Asia, South America, and Malta, followed by lower prevalence rates (25-50) in Australia, China, Africa, Romania, Greece, Italy, and Portugal (3). The prevalence rate of MRSA in Malaysia has been reported to increase from 17 in 1986 (4) to 44 in 2007 (5). To date, healthcare-associated MRSA (HA-MRSA) remains a global healthcare concern; however, the emergence of community-associated MRSA (CA-MRSA) since the 1990s poses significant risks and threats to both hospital and community populations. The current modality of treatment for MRSA infections is prescribing antibiotics, such as vancomycin, linezolid, rifampicin, and fusidic acid (2,6). The molecular epidemiology of MRSA can be studied using different typing methods, such as staphylococcal cassette chromosomal mec (SCCmec) typing, multilocus sequence typing (MLST), and pulsed